BofA Securities调整了对Hims and Hers (NYSE:HIMS)的展望，将目标价从20.00美元上调至23.00美元，并维持买入评级。这一调整是基于美国食品和药物管理局（FDA）最近宣布重新评估曾列入短缺清单的tirzepatide药物的可用性。 FDA在周五的一份法庭文件中表示，将重新考虑早前将tirzepatide从短缺清单中移除的决定。该机构还指出，在审查该活性成分的 ...

Leerink Partners维持礼来(NYSE: LLY)股票"跑赢大市"评级，目标价保持在$990.00不变。该公司在预期礼来第三季度业绩时调整了其财务模型。

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

Nearly 250,000 people in England could access a weight loss injection on the NHS. Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss.